| pubmed-article:3172135 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3172135 | lifeskim:mentions | umls-concept:C0000854 | lld:lifeskim |
| pubmed-article:3172135 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:3172135 | lifeskim:mentions | umls-concept:C0007732 | lld:lifeskim |
| pubmed-article:3172135 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:3172135 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:3172135 | pubmed:dateCreated | 1988-11-18 | lld:pubmed |
| pubmed-article:3172135 | pubmed:abstractText | The structure-activity relationship for 7-arylacetamido cephalosporins has been extended. Modifications of the 7-aryl group led to improvements in microbiological activity against Gram-positive organisms. However, Gram-negative activity was generally much poorer than that of the lead compound 7-[(2-aminothiazol-4-yl)acetamido]-3-chloro-cephalosporanic acid (A). Modifications of the 3-position did not significantly change the microbiological activity or spectrum. Of the compounds selected for mouse protection studies (ED50's), 7-[(benzothien-3-yl)acetamido]-3-chloro cephalosporin and A showed the best per oral to subcutaneous ED50 ratios. | lld:pubmed |
| pubmed-article:3172135 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3172135 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3172135 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3172135 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3172135 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3172135 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:3172135 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:3172135 | pubmed:author | pubmed-author:KukoljaSS | lld:pubmed |
| pubmed-article:3172135 | pubmed:author | pubmed-author:OttJ LJL | lld:pubmed |
| pubmed-article:3172135 | pubmed:author | pubmed-author:CounterF TFT | lld:pubmed |
| pubmed-article:3172135 | pubmed:author | pubmed-author:DraheimS ESE | lld:pubmed |
| pubmed-article:3172135 | pubmed:author | pubmed-author:Pfeil-DoyleJJ | lld:pubmed |
| pubmed-article:3172135 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3172135 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:3172135 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3172135 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3172135 | pubmed:pagination | 1993-7 | lld:pubmed |
| pubmed-article:3172135 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:meshHeading | pubmed-meshheading:3172135-... | lld:pubmed |
| pubmed-article:3172135 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3172135 | pubmed:articleTitle | Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins. | lld:pubmed |
| pubmed-article:3172135 | pubmed:affiliation | Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285. | lld:pubmed |
| pubmed-article:3172135 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:3172135 | lld:chembl |
